Cargando…

Clinical Outcomes of BCMA CAR-T Cells in a Multiple Myeloma Patient With Central Nervous System Invasion

BACKGROUND: Multiple myeloma (MM) is the second most common hematological malignancy that still lacks effective clinical treatments. In particular, MM with central nervous system (CNS) invasion occurs rarely. Although B-cell maturation antigen (BCMA)-targeted chimeric antigen receptor-T (CAR-T) cell...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Ting, He, Ting, Ma, Lie, Yang, Yazi, Feng, Ru, Ding, Yanping, Shan, Yueming, Bu, Bing, Qi, Feifei, Wu, Fei, Lu, Xin-an, Liu, Hui
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9150173/ https://www.ncbi.nlm.nih.gov/pubmed/35651792 http://dx.doi.org/10.3389/fonc.2022.854448

Ejemplares similares

Successful BCMA CAR-T Therapy for Multiple Myeloma With Central Nervous System Involvement Manifesting as Cauda Equina Syndrome—A Wandering Road to Remission
por: Wang, Yiyun, et al.
Publicado: (2021)

Early Dynamics and Depth of Response in Multiple Myeloma Patients Treated With BCMA CAR-T Cells
por: Wong, Sandy W., et al.
Publicado: (2021)

Innovation in BCMA CAR-T therapy: Building beyond the Model T
por: Banerjee, Rahul, et al.
Publicado: (2022)

Single VHH-directed BCMA CAR-NK cells for multiple myeloma
por: Ren, Quan, et al.
Publicado: (2023)

Safety and clinical efficacy of BCMA CAR-T-cell therapy in multiple myeloma
por: Roex, Gils, et al.
Publicado: (2020)

Case report: Plasma cell leukemia secondary to multiple myeloma successfully treated with anti-BCMA CAR-T cell therapy
por: Deng, Jingjing, et al.
Publicado: (2022)

sBCMA Plasma Level Dynamics and Anti-BCMA CAR-T-Cell Treatment in Relapsed Multiple Myeloma
por: Seipel, Katja, et al.
Publicado: (2022)

“Waitlist mortality” is high for myeloma patients with limited access to BCMA therapy
por: Ahmed, Nausheen, et al.
Publicado: (2023)

Anti‑BCMA CAR‑T cell immunotherapy for relapsed or refractory multiple myeloma
por: Zhang, Xiaohui, et al.
Publicado: (2023)

Driving CARs to new places: locally produced BCMA CAR T cells to treat multiple myeloma
por: Sjöstrand, Maria, et al.
Publicado: (2023)

Anti-BCMA CAR T-cell Therapy: Changing the Natural History of Multiple Myeloma
por: Puertas, Borja, et al.
Publicado: (2022)

Preclinical evaluation and structural optimization of anti-BCMA CAR to target multiple myeloma
por: Harush, Ortal, et al.
Publicado: (2022)

Single VHH-directed BCMA CAR-T cells cause remission of relapsed/refractory multiple myeloma
por: Han, Lu, et al.
Publicado: (2021)

CAR-T-Cell Therapy in Multiple Myeloma: B-Cell Maturation Antigen (BCMA) and Beyond
por: Mishra, Abhinava K., et al.
Publicado: (2023)

P1410: EFFICACY OBSERVATION OF A SECOND INFUSION OF BCMA-CAR-T CELLS IN PATIENTS WITH REFRACTORY/RELAPSED MULTIPLE MYELOMA
por: Wang, Yi, et al.
Publicado: (2023)

Immunoglobulin isotype switch after anti-BCMA CAR T-cell therapy for relapsed or refractory multiple myeloma
por: Liang, Zhiyu, et al.
Publicado: (2022)

All-trans retinoic acid works synergistically with the γ-secretase inhibitor crenigacestat to augment BCMA on multiple myeloma and the efficacy of BCMA-CAR T cells
por: García-Guerrero, Estefanía, et al.
Publicado: (2022)

Efficacy of Humanized Anti-BCMA CAR T Cell Therapy in Relapsed/Refractory Multiple Myeloma Patients With and Without Extramedullary Disease
por: Deng, Haobin, et al.
Publicado: (2021)

Novel CS1 CAR-T Cells and Bispecific CS1-BCMA CAR-T Cells Effectively Target Multiple Myeloma
por: Golubovskaya, Vita, et al.
Publicado: (2021)

CAR-T Cells Based on Novel BCMA Monoclonal Antibody Block Multiple Myeloma Cell Growth
por: Berahovich, Robert, et al.
Publicado: (2018)

BCMA-Directed CAR T Cells in Relapsed Refractory Multiple Myeloma: Highlights From SOHO 2021
Publicado: (2022)

Armored BCMA CAR T Cells Eliminate Multiple Myeloma and Are Resistant to the Suppressive Effects of TGF-β
por: Alabanza, Leah M., et al.
Publicado: (2022)

Infectious complications in patients with relapsed refractory multiple myeloma after BCMA CAR T-cell therapy
por: Kambhampati, Swetha, et al.
Publicado: (2022)

High efficacy and safety of CD38 and BCMA bispecific CAR-T in relapsed or refractory multiple myeloma
por: Tang, Yuanyan, et al.
Publicado: (2022)

Bendamustine vs. fludarabine/cyclophosphamide lymphodepletion prior to BCMA CAR-T cell therapy in multiple myeloma
por: Sidana, Surbhi, et al.
Publicado: (2023)

Single-cell transcriptomic atlas throughout anti-BCMA CAR-T therapy in patients with multiple myeloma
por: Xia, Yuan, et al.
Publicado: (2023)

Teclistamab impairs detection of BCMA CAR-T cells
por: Glatte, Bettina, et al.
Publicado: (2023)

Oncolytic herpes simplex virus delivery of dual CAR targets of CD19 and BCMA as well as immunomodulators to enhance therapeutic efficacy in solid tumors combined with CAR T cell therapy
por: Liu, Yuanyuan, et al.
Publicado: (2022)

Anti-BCMA/CD19 CAR T Cells with Early Immunomodulatory Maintenance for Multiple Myeloma Responding to Initial or Later-Line Therapy
por: Garfall, Alfred L., et al.
Publicado: (2023)

BCMA-targeted immunotherapy for multiple myeloma
por: Yu, Bo, et al.
Publicado: (2020)

Systematically optimized BCMA/CS1 bispecific CAR-T cells robustly control heterogeneous multiple myeloma
por: Zah, Eugenia, et al.
Publicado: (2020)

Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma
por: Samur, Mehmet Kemal, et al.
Publicado: (2021)

Preclinical evaluation of CD8+ anti-BCMA mRNA CAR T-cells for treatment of multiple myeloma
por: Lin, Liang, et al.
Publicado: (2020)

A bispecific CAR-T cell therapy targeting BCMA and CD38 in relapsed or refractory multiple myeloma
por: Mei, Heng, et al.
Publicado: (2021)

Humoral immune reconstitution after anti-BCMA CAR T-cell therapy in relapsed/refractory multiple myeloma
por: Wang, Ying, et al.
Publicado: (2021)

Ciltacabtagene autoleucel: The second anti-BCMA CAR T-cell therapeutic armamentarium of relapsed or refractory multiple myeloma
por: Chekol Abebe, Endeshaw, et al.
Publicado: (2022)

Both APRIL and antibody-fragment-based CAR T cells for myeloma induce BCMA downmodulation by trogocytosis and internalization
por: Camviel, Nicolas, et al.
Publicado: (2022)

Safe and successful CAR T-cell therapy targeting BCMA in a multiple myeloma patient requiring hemodialysis
por: Wäsch, Ralph, et al.
Publicado: (2023)

Anti-TACI single and dual-targeting CAR T cells overcome BCMA antigen loss in multiple myeloma
por: Larson, Rebecca C., et al.
Publicado: (2023)

The CAR-HEMATOTOX score as a prognostic model of toxicity and response in patients receiving BCMA-directed CAR-T for relapsed/refractory multiple myeloma
por: Rejeski, Kai, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ujf364dohtcblf0ashkn9pi9rb